

given to charge Deposit Account No. 23-1701 in the amount of Four Hundred Dollars (\$400.00)

to cover the corresponding extension fee pursuant to 37 C.F.R. §§1.17(a)(2) and 1.136(a).


**OFFICIAL****FAX RECEIVED**

AUG 16 2002

**GROUP 1600****IN THE CLAIMS:**


Substitute claims 1, 18, 26 and 27 with amended claims 1, 18, 26 and 27:

81  
1. (Four times amended) A method of treatment for improving the inhibition of gastric acid secretion which comprises administering to a host in need thereof an oral pharmaceutical formulation comprising a therapeutically effective amount of an acid labile  $H^+$ ,  $K^+$ -ATPase inhibitor, wherein the method induces an extended blood plasma profile of the  $H^+$ ,  $K^+$ -ATPase inhibitor, and the  $H^+$ ,  $K^+$ -ATPase inhibitor is a compound of the formula I




wherein

Het<sub>1</sub> is




or




Het<sub>2</sub> is


*Sub  
J1  
cont*



or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;

*E1  
cont.* R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub>; and


R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from the group consisting of hydrogen, halogen or alkyl.

18. (Thrice amended) A method of treatment for improving the inhibition of gastric acid secretion which comprises administering to a host in need thereof an oral pharmaceutical formulation comprising a therapeutically effective amount of an acid labile  $H^+$ ,  $K^+$ -ATPase inhibitor, wherein the method induces an extended blood plasma profile of the  $H^+$ ,  $K^+$ -ATPase inhibitor, and the  $H^+$ ,  $K^+$ -ATPase inhibitor is a compound of the formula I




wherein

Het<sub>1</sub> is




or




Het<sub>2</sub> is


*Sub  
32  
cont*




or



X =



or



*Ed  
Concl* wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxy carbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub>; and

R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from the group consisting of hydrogen, halogen or alkyl


with the proviso that the H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor is not pantoprazole.

26. (Twice amended) A method for improving the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a host in need thereof an oral pharmaceutical formulation comprising a therapeutically effective amount of an acid labile  $H^+$ ,  $K^+$ -ATPase inhibitor, wherein the method induces an extended blood plasma profile of the  $H^+$ ,  $K^+$ -ATPase inhibitor, and the  $H^+$ ,  $K^+$ -ATPase inhibitor is a compound of the formula I




wherein


$Het_1$  is




or




$Het_2$  is




or



*Sub 33 cont*  
X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;


R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

*93* R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub>; and

R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from the group consisting of hydrogen, halogen or alkyl.


27. (Twice amended) A method for improving the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to host in need thereof an oral pharmaceutical formulation comprising a therapeutically effective amount of an acid labile H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor, wherein the method induces an extended blood plasma profile of the H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor, and the H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor is a compound of the formula I




I

wherein


Het<sub>1</sub> is




or




Het<sub>2</sub> is




or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;